{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:52:35Z","timestamp":1792183955576,"version":"4.4.0"},"reference-count":98,"publisher":"Oxford University Press (OUP)","issue":"1014","license":[{"start":{"date-parts":[[2010,3,30]],"date-time":"2010-03-30T00:00:00Z","timestamp":1269907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Management of rheumatoid arthritis (RA) has radically changed over the last decade. Diagnostic methods have improved with availability of highly specific tests such as antibody to cyclic citrullinated peptide (specificity \u223c96%), and introduction of advanced imaging modalities such as ultrasound and magnetic resonance imaging to facilitate earlier diagnosis. The current aim of management is to achieve remission and prevent joint damage. In order to achieve this goal, inflammation is suppressed as much as possible during the early phase of the disease before onset of joint damage. Aggressive treatments with combinations of disease modifying anti-rheumatic drugs are commenced earlier in the course of disease, and tight control maintained with regular objective monitoring of disease activity. Early use of anti-TNF\u03b1 (tumour necrosis factor \u03b1) therapy in combination with methotrexate helps to achieve better clinical and radiographic outcomes, which can be maintained for up to 5 years after withdrawal of anti-TNF\u03b1 therapy. Apart from anti-TNF\u03b1, several other biological treatments are now available, including those that target CD20 on B cells (rituximab), cytokines such as IL1 (anakinra) and IL6 (tocilizumab), and molecules that cause interaction between antigen presenting cells and T cells (abatacept). There is better awareness and understanding of RA associated complications such as cardiovascular disease and osteoporosis. Use of non-steroidal anti-inflammatory drugs is on the decline in light of recent concerns about cardiovascular safety. Evidence is emerging in support of statins and bisphosphonates for improving RA disease activity and preventing erosions, respectively. In the coming years, further improvements in therapeutic strategies are likely with the pace at which research is currently progressing.<\/jats:p>","DOI":"10.1136\/pgmj.2009.090399","type":"journal-article","created":{"date-parts":[[2010,3,30]],"date-time":"2010-03-30T09:32:36Z","timestamp":1269941556000},"page":"243-250","source":"Crossref","is-referenced-by-count":15,"title":["Recent advances in rheumatoid arthritis"],"prefix":"10.1093","volume":"86","author":[{"given":"Ernest","family":"Suresh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2010,3,30]]},"reference":[{"key":"2023041908463460600_b1","first-page":"565","article-title":"Remodelling the pyramid- a concept whose time has come","volume":"16","author":"Wilske","year":"1989","journal-title":"J Rheumatol"},{"key":"2023041908463460600_b2","first-page":"585","article-title":"Evidence of significant radiographic damage in rheumatoid arthritis within the first 2\u2005years of disease","volume":"16","author":"Fuchs","year":"1989","journal-title":"J Rheumatol"},{"key":"2023041908463460600_b3","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.1780350105","article-title":"Biannual radiographic assessments of hands and feet in a three-year prospective follow-up of patients with early rheumatoid arthritis","volume":"35","author":"van der Heijde","year":"1992","journal-title":"Arthritis Rheum"},{"key":"2023041908463460600_b4","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1136\/ard.57.6.350","article-title":"Magnetic imaging of the wrist in early rheumatoid arthritis reveals a high prevalence of erosions at four months after symptom onset","volume":"57","author":"McQueen","year":"1998","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"2023041908463460600_b5","first-page":"121","article-title":"The majority of patients with rheumatoid arthritis have erosive disease at presentation when magnetic resonance imaging of the dominant hand is employed","volume":"36","author":"McGonagle","year":"1997","journal-title":"Br J Rheumatol"},{"key":"2023041908463460600_b6","doi-asserted-by":"crossref","first-page":"699","DOI":"10.7326\/0003-4819-124-8-199604150-00001","article-title":"The effectiveness of early treatment with \u201csecond line\u201d antirheumatic drugs. A randomised, controlled trial","volume":"124","author":"van der Heide","year":"1996","journal-title":"Ann Intern Med"},{"key":"2023041908463460600_b7","first-page":"2208","article-title":"Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5-year follow-up of a prospective double blind placebo controlled study","volume":"22","author":"Egsmose","year":"1995","journal-title":"J Rheumatol"},{"key":"2023041908463460600_b8","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1093\/rheumatology\/keh199","article-title":"Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis","volume":"43","author":"Nell","year":"2004","journal-title":"Rheumatology"},{"key":"2023041908463460600_b9","doi-asserted-by":"crossref","first-page":"773","DOI":"10.7326\/0003-4819-124-8-199604150-00012","article-title":"Rheumatoid arthritis: treat now, not later!","volume":"124","author":"Weinblatt","year":"1996","journal-title":"Ann Intern Med"},{"key":"2023041908463460600_b10","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1177\/014107680409700903","article-title":"Diagnosis of early rheumatoid arthritis: what the non-specialist needs to know","volume":"97","author":"Suresh","year":"2004","journal-title":"J R Soc Med"},{"key":"2023041908463460600_b11","first-page":"1436","article-title":"The Dunlop-Dottridge Lecture. Prognosis in inflammatory arthritis: the value of HLA genotyping and the oncological analogy","volume":"24","author":"Emery","year":"1997","journal-title":"J Rheumatol"},{"key":"2023041908463460600_b12","first-page":"994","article-title":"Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts","volume":"17","author":"Wolfe","year":"1990","journal-title":"J Rheumatol"},{"key":"2023041908463460600_b13","first-page":"1885","article-title":"Long term drug therapy for rheumatoid arthritis in seven rheumatology private practices: II second line drugs and prednisolone","volume":"19","author":"Pincus","year":"1992","journal-title":"J Rheumatol"},{"issue":"Suppl 2","key":"2023041908463460600_b14","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/rheumatology\/XXXIV.suppl_2.43","article-title":"Efficacy of methotrexate in rheumatoid arthritis","volume":"34","author":"Weinblatt","year":"1995","journal-title":"Br J Rheumatol"},{"key":"2023041908463460600_b15","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/art.10998","article-title":"Declining use of orthopaedic surgery in patients with rheumatoid arthritis? Results of a long-term population based assessment","volume":"49","author":"da Silva","year":"2003","journal-title":"Arthritis Rheum"},{"key":"2023041908463460600_b16","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/ard.2005.039420","article-title":"Orthopaedic surgery of the lower limbs in 49 802 rheumatoid arthritis patients: results from the Swedish National Inpatient registry during 1987 to 2001","volume":"65","author":"Weiss","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"2023041908463460600_b17","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2105\/AJPH.15.7.631-a","article-title":"The gold treatment of tuberculosis","volume":"15","year":"1925","journal-title":"Am J Public Health"},{"key":"2023041908463460600_b18","first-page":"713","article-title":"Guidelines for the management of rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines","volume":"39","year":"1996","journal-title":"Arthritis Rheum"},{"key":"2023041908463460600_b19","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/1529-0131(200112)44:12<2737::AID-ART460>3.0.CO;2-#","article-title":"High incidence of cardiovascular events in rheumatoid arthritis cohort not explained by traditional cardiac risk factors","volume":"44","author":"del Rincon","year":"2001","journal-title":"Arthritis Rheum"},{"key":"2023041908463460600_b20","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/art.1780370408","article-title":"The mortality of rheumatoid arthritis","volume":"37","author":"Wolfe","year":"1994","journal-title":"Arthritis Rheum"},{"key":"2023041908463460600_b21","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/art.10613","article-title":"Management of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis: rates and predictors of care in an academic rheumatology practice","volume":"46","author":"Solomon","year":"2002","journal-title":"Arthritis Rheum"},{"key":"2023041908463460600_b22","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/qjmed\/hcm015","article-title":"Anti-CCP antibody testing as a diagnostic and prognostic tool in rheumatoid arthritis","volume":"100","author":"Niewold","year":"2007","journal-title":"QJM"},{"key":"2023041908463460600_b23","first-page":"231","article-title":"Predictive value of antibodies to cyclic citrullinated peptide in patients with very early rheumatoid arthritis","volume":"32","author":"Raza","year":"2005","journal-title":"J Rheumatol"},{"key":"2023041908463460600_b24","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/rheumatology\/kei203","article-title":"Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predicts radiological and functional outcome","volume":"45","author":"Quinn","year":"2006","journal-title":"Rheumatology"},{"key":"2023041908463460600_b25","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/1529-0131(200001)43:1<155::AID-ANR20>3.0.CO;2-3","article-title":"The diagnostic properties of rheumatoid arthritis antibodies recognising a cyclic citrullinated peptide","volume":"43","author":"Schellekens","year":"2000","journal-title":"Arthritis Rheum"},{"key":"2023041908463460600_b26","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/03009740310000058","article-title":"Imaging in rheumatoid arthritis- why MRI and ultrasound can no longer be ignored","volume":"32","author":"Ostergaard","year":"2003","journal-title":"Scand J Rheumatol"},{"key":"2023041908463460600_b27","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1002\/art.11162","article-title":"Bone oedema scored on magnetic resonance imaging scans of the dominant carpus at presentation predicts radiographic joint damage of the hands and feet six years later in patients with rheumatoid arthritis","volume":"48","author":"McQueen","year":"2003","journal-title":"Arthritis Rheum"},{"key":"2023041908463460600_b28","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/ar2778","article-title":"Predicting joint damage in rheumatoid arthritis using MRI scanning","volume":"11","author":"McQueen","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"2023041908463460600_b29","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1002\/art.20333","article-title":"Ultrasonography of the metatarsophalangeal joints in rheumatoid arthritis: comparison with magnetic resonance imaging, conventional radiography, and clinical examination","volume":"50","author":"Szkudlarek","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2023041908463460600_b30","first-page":"743","article-title":"Ultrasonography detection of early bone erosions in the metacarpophalangeal joints of patients with rheumatoid arthritis","volume":"22","author":"Magnani","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"2023041908463460600_b31","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1136\/ard.2005.035691","article-title":"Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis","volume":"64","author":"Nell","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2023041908463460600_b32","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1002\/1529-0131(199910)42:10<2184::AID-ANR20>3.0.CO;2-2","article-title":"Persistence of mild, early inflammatory arthritis: the importance of disease duration, rheumatoid factor and the shared epitope","volume":"42","author":"Green","year":"1999","journal-title":"Arthritis Rheum"},{"key":"2023041908463460600_b33","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/art.10117","article-title":"How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) disease","volume":"46","author":"Visser","year":"2002","journal-title":"Arthritis Rheum"},{"key":"2023041908463460600_b34","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1136\/ard.2008.092676","article-title":"Validation of a prediction rule for development of rheumatoid arthritis in patients with early undifferentiated arthritis","volume":"68","author":"Kuriya","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2023041908463460600_b35","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1136\/ard.2004.032219","article-title":"Combination treatment strategies in early rheumatoid arthritis","volume":"64","author":"Suresh","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2023041908463460600_b36","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1002\/art.21405","article-title":"Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial","volume":"52","author":"Goekoop-Ruiterman","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2023041908463460600_b37","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(97)01300-7","article-title":"Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis","volume":"350","author":"Boers","year":"1997","journal-title":"Lancet"},{"key":"2023041908463460600_b38","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/S0140-6736(98)08513-4","article-title":"Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group","volume":"353","author":"Mottonen","year":"1999","journal-title":"Lancet"},{"key":"2023041908463460600_b39","first-page":"699","article-title":"Combination therapy versus monotherapy for the treatment of patients with rheumatoid arthritis","volume":"17","author":"Calguneri","year":"1999","journal-title":"Clin Exp Rheumatol"},{"key":"2023041908463460600_b40","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJM199605163342002","article-title":"Treatment of rheumatoid arthritis with methotrexate alone, sulphasalazine and hydroxychloroquine, or a combination of all three medications","volume":"334","author":"O\u2019Dell","year":"1996","journal-title":"N Engl J Med"},{"key":"2023041908463460600_b41","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/art.21655","article-title":"Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial","volume":"54","author":"van der Heijde","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2023041908463460600_b42","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1002\/art.20568","article-title":"Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial","volume":"50","author":"St Clair","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2023041908463460600_b43","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","article-title":"The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment","volume":"54","author":"Breedveld","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2023041908463460600_b44","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/art.10083","article-title":"COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention","volume":"46","author":"Landewe","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"5 Suppl 31","key":"2023041908463460600_b45","first-page":"S179","article-title":"Methotrexate as the \u201canchor drug\u201d for the treatment of early rheumatoid arthritis","volume":"21","author":"Pincus","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"2023041908463460600_b46","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60784-3","article-title":"New therapies for treatment of rheumatoid arthritis","volume":"360","author":"Smolen","year":"2007","journal-title":"Lancet"},{"key":"2023041908463460600_b47","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1136\/ard.2008.094474","article-title":"Multinational evidence based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systemic literature research and expert opinion of a broad international panel of rheumatologists in the 3E initiative","volume":"68","author":"Visser","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2023041908463460600_b48","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/S0140-6736(09)60944-2","article-title":"Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial","volume":"374","author":"van Vollenhoven","year":"2009","journal-title":"Lancet"},{"key":"2023041908463460600_b49","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(08)61000-4","article-title":"Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial","volume":"372","author":"Emery","year":"2008","journal-title":"Lancet"},{"key":"2023041908463460600_b50","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1136\/ard.2008.093294","article-title":"Clinical and radiological efficacy of initial vs delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis","volume":"68","author":"van der Kooij","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2023041908463460600_b51","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1136\/ard.2008.092254","article-title":"Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis","volume":"68","author":"van der Kooij","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2023041908463460600_b52","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(04)16676-2","article-title":"Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial","volume":"364","author":"Grigor","year":"2004","journal-title":"Lancet"},{"key":"2023041908463460600_b53","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1161\/ATVBAHA.109.190108","article-title":"Atherosclerosis in rheumatoid arthritis versus diabetes. A comparative study","volume":"29","author":"Stamatelopoulos","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2023041908463460600_b54","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/rheumatology\/31.5.293","article-title":"TNF alpha\u2014a pivotal role in rheumatoid arthritis?","volume":"31","author":"Brennan","year":"1992","journal-title":"Br J Rheumatol"},{"key":"2023041908463460600_b55","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1191\/0961203306lu2278rr","article-title":"The world of biologics","volume":"15","author":"Symmons","year":"2006","journal-title":"Lupus"},{"issue":"Suppl 2","key":"2023041908463460600_b56","doi-asserted-by":"crossref","first-page":"ii55","DOI":"10.1136\/ard.62.suppl_2.ii55","article-title":"B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience","volume":"62","author":"Shaw","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"2023041908463460600_b57","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1136\/ard.2006.061002","article-title":"Consensus statement on the use of rituximab in patients with rheumatoid arthritis","volume":"66","author":"Smolen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2023041908463460600_b58","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"2023041908463460600_b59","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2023041908463460600_b60","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1136\/ard.2007.085787","article-title":"Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies","volume":"68","author":"Keystone","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2023041908463460600_b61","doi-asserted-by":"crossref","first-page":"865","DOI":"10.7326\/0003-4819-144-12-200606200-00003","article-title":"Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis","volume":"144","author":"Kremmer","year":"2006","journal-title":"Ann Intern Med"},{"key":"2023041908463460600_b62","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1002\/art.22033","article-title":"Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate","volume":"54","author":"Maini","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2023041908463460600_b63","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/S0140-6736(08)60629-7","article-title":"NICE and new drugs for rheumatoid arthritis","volume":"371","year":"2008","journal-title":"Lancet"},{"key":"2023041908463460600_b64","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1136\/ard.2008.101659","article-title":"Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial","volume":"68","author":"Smolen","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2023041908463460600_b65","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1136\/ard.2008.099291","article-title":"Efficacy and safety of certolizumab pegol monotherapy every 4\u2005weeks in patients with rheumatoid arthritis failing previous disease-modifying anti-rheumatic therapy: the FAST4WARD study","volume":"68","author":"Fleischmann","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2023041908463460600_b66","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0140-6736(09)60506-7","article-title":"Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre randomised, double blind, placebo controlled phase III trial","volume":"374","author":"Smolen","year":"2009","journal-title":"Lancet"},{"key":"2023041908463460600_b67","first-page":"210","article-title":"Emerging therapeutics for rheumatoid arthritis","volume":"66","author":"Bingham","year":"2008","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"2023041908463460600_b68","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/art.23417","article-title":"Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomised, double-blind, placebo-controlled, phase II clinical trial","volume":"58","author":"Cohen","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2023041908463460600_b69","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nrrheum.2009.82","article-title":"Tyrosine kinases as targets for the treatment of rheumatoid arthritis","volume":"5","author":"D\u2019Aura Swanson","year":"2009","journal-title":"Nat Rev Rheumatol"},{"key":"2023041908463460600_b70","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/art.10089","article-title":"Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis?","volume":"46","author":"Van Doornum","year":"2002","journal-title":"Arthritis Rheum"},{"key":"2023041908463460600_b71","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.atherosclerosis.2006.09.027","article-title":"Acceleration of atherosclerosis during the course of rheumatoid arthritis","volume":"195","author":"del Rincon","year":"2007","journal-title":"Atherosclerosis"},{"key":"2023041908463460600_b72","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1161\/01.CIR.0000099844.31524.05","article-title":"Explaining how \u201chigh grade\u201d systemic inflammation accelerates vascular risk in rheumatoid arthritis","volume":"108","author":"Sattar","year":"2003","journal-title":"Circulation"},{"key":"2023041908463460600_b73","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1253\/circj.CJ-09-0274","article-title":"Rheumatoid arthritis\u2014a model of systemic inflammation driving atherosclerosis","volume":"79","author":"Ku","year":"2009","journal-title":"Circ J"},{"key":"2023041908463460600_b74","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1161\/01.CIR.0000125690.80303.A8","article-title":"Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores","volume":"109","author":"Ridker","year":"2004","journal-title":"Circulation"},{"key":"2023041908463460600_b75","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1093\/rheumatology\/kei012","article-title":"Disease modification and cardiovascular risk reduction: two sides of the same coin?","volume":"44","author":"Hall","year":"2005","journal-title":"Rheumatology"},{"key":"2023041908463460600_b76","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"2023041908463460600_b77","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/art.21521","article-title":"Statins as anti-inflammatory and immunomodulatory agents: a future in rheumatologic therapy?","volume":"54","author":"Abeles","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2023041908463460600_b78","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(04)16449-0","article-title":"Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial","volume":"363","author":"McCarey","year":"2004","journal-title":"Lancet"},{"key":"2023041908463460600_b79","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1056\/NEJMp048288","article-title":"Coxibs and cardiovascular disease","volume":"351","author":"Fitzgerald","year":"2004","journal-title":"N Engl J Med"},{"key":"2023041908463460600_b80","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1136\/bmj.330.7504.1366","article-title":"Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population bases nested case-control analysis","volume":"330","author":"Hippisley-Cox","year":"2005","journal-title":"BMJ"},{"key":"2023041908463460600_b81","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1161\/CIRCULATIONAHA.106.181424","article-title":"Use of nonsteroidal anti-inflammatory drugs: an update for clinicians. A scientific statement from the American Heart Association","volume":"115","author":"Antman","year":"2007","journal-title":"Circulation"},{"key":"2023041908463460600_b82","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/01.bor.0000127824.42507.68","article-title":"Bone loss in inflammatory arthritis: mechanisms and treatment strategies","volume":"16","author":"Walsh","year":"2004","journal-title":"Curr Opin Rheumatol"},{"key":"2023041908463460600_b83","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1136\/ard.2007.085985","article-title":"Cortical hand bone loss after 1\u2005year in early rheumatoid arthritis predicts radiographic hand joint damage at 5-year and 10-year follow-up","volume":"68","author":"Hoff","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2023041908463460600_b84","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1002\/art.22117","article-title":"Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis","volume":"54","author":"van Staa","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2023041908463460600_b85","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jbspin.2005.10.019","article-title":"Bisphosphonate therapy in rheumatoid arthritis","volume":"73","author":"Breuil","year":"2006","journal-title":"Joint Bone Spine"},{"key":"2023041908463460600_b86","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1002\/art.21824","article-title":"Preliminary evidence for a structural benefit of the new bisphosphonate zolendronic acid in early rheumatoid arthritis","volume":"54","author":"Jarret","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2023041908463460600_b87","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00198-007-0543-5","article-title":"FRAX and the assessment of fracture probability in men and women from the UK","volume":"19","author":"Kanis","year":"2008","journal-title":"Osteoporosis Int"},{"issue":"Suppl 2","key":"2023041908463460600_b88","first-page":"138","article-title":"The impact of the publication of SIGN guideline on management of early rheumatoid arthritis","volume":"43","author":"Suresh","year":"2004","journal-title":"Rheumatology"},{"key":"2023041908463460600_b89","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1002\/art.22979","article-title":"The widening mortality gap between rheumatoid arthritis patients and the general population","volume":"56","author":"Gonzalez","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2023041908463460600_b90","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11845-008-0252-x","article-title":"Limiting cardiovascular risk in Irish rheumatoid arthritis patients","volume":"178","author":"Ambrose","year":"2009","journal-title":"Ir J Med Sci"},{"key":"2023041908463460600_b91","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/nrrheum.2009.29","article-title":"Management of cardiovascular disease risk in chronic inflammatory disorders","volume":"5","author":"Kaplan","year":"2009","journal-title":"Nat Rev Rheumatol"},{"key":"2023041908463460600_b92","first-page":"174","article-title":"Personalized medicine in rheumatoid arthritis: hopes and challenges","volume":"65","author":"Bridges","year":"2007","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"2023041908463460600_b93","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1093\/rheumatology\/kep155","article-title":"A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis","volume":"48","author":"Vastesaeger","year":"2009","journal-title":"Rheumatology"},{"key":"2023041908463460600_b94","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/art.20712","article-title":"Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve month randomised double-blind placebo controlled trial","volume":"52","author":"Quinn","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2023041908463460600_b95","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/ard.57.4.209","article-title":"HLA-DRB1 typing in rheumatoid arthritis: predicting response to specific treatments","volume":"57","author":"O\u2019Dell","year":"1998","journal-title":"Ann Rheum Dis"},{"key":"2023041908463460600_b96","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/art.22525","article-title":"Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomised, placebo-controlled trial","volume":"56","author":"van Dongen","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2023041908463460600_b97","doi-asserted-by":"crossref","first-page":"iv106","DOI":"10.1136\/ard.2005.042408","article-title":"The 2005 International Symposium on Advances in Targeted Therapies: what have we learnt in the 2000s and where are we going?","volume":"64","author":"Maini","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2023041908463460600_b98","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1089\/hum.2008.075","article-title":"Clinical responses to gene therapy in joints of two subjects with rheumatoid arthritis","volume":"20","author":"Wehling","year":"2009","journal-title":"Hum Gene Ther"}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/86\/1014\/243\/50022314\/postgradmedj-86-243.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/86\/1014\/243\/50022314\/postgradmedj-86-243.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T19:31:27Z","timestamp":1739993487000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/article\/86\/1014\/243\/7129223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,30]]},"references-count":98,"journal-issue":{"issue":"1014","published-online":{"date-parts":[[2010,3,30]]},"published-print":{"date-parts":[[2010,4,1]]}},"URL":"https:\/\/doi.org\/10.1136\/pgmj.2009.090399","relation":{},"ISSN":["0032-5473","1469-0756"],"issn-type":[{"value":"0032-5473","type":"print"},{"value":"1469-0756","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2010,4]]},"published":{"date-parts":[[2010,3,30]]}}}